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Abstract
Intracellular protein levels of p53 and MDM2 have been shown to oscillate in response to ionizing radiation (IR), but the
physiological significance of these oscillations remains unclear. The p53-MDM2 negative feedback loop – the putative cause
of the oscillations – is embedded in a network involving a mutual antagonism (or positive feedback loop) between p53 and
AKT. We have shown earlier that this p53-AKT network predicts an all-or-none switching behavior between a pro-survival
cellular state (low p53 and high AKT levels) and a pro-apoptotic state (high p53 and low AKT levels). Here, we show that
upon exposure to IR, the p53-AKT network can also reproduce the experimentally observed p53 and MDM2 oscillations. The
present work is based on the hypothesis that the physiological significance of the experimentally observed oscillations
could be found in their role in regulating the switching behavior of the p53-AKT network between pro-survival and pro-
apoptotic states. It is shown here that these oscillations are associated with a significant decrease in the threshold level of IR
at which switching from a pro-survival to a pro-apoptotic state occurs. Moreover, oscillations in p53 protein levels induce
higher levels of expression of p53-target genes compared to non-oscillatory p53, and thus influence cell-fate decisions
between cell cycle arrest/DNA damage repair versus apoptosis.
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Introduction
In response to DNA damage from exposure to ultraviolet (UV)
or ionizing radiation (IR), damped oscillations in the levels of p53
and MDM2 proteins have been observed in populations of cells
such as fibroblasts (human and mouse) and MCF7 breast cancer
cells [1,2]. Isolated single cells exhibit oscillations that are more
sustained, sometimes lasting more than three days, depending on
the persistence of DNA damage [3]. The frequencies of these
oscillations generally increase with increasing IR intensity, and
oscillation periods are typically in the range of 4 to 7 hrs; unlike
this narrow range in the observed periods, the amplitudes of p53
oscillations are quite variable. Because it is the number of
oscillations rather than their amplitudes that is observed to be
dependent on the dose of IR, p53 oscillations have been described
as ‘digital’. MDM2 oscillations are coupled with the p53
oscillations, with corresponding peaks separated by 1.5 to
2.5 hrs. Similar observations have also been observed in vivo in
mouse intestine and spleen [4] where damped p53 pulses with
periods of 4.5 to 6 hrs are reported.
The putative mechanistic origin of the oscillations is the
negative feedback loop between p53 and MDM2 [1,3,5–9].
Transcriptional activity of p53 induces MDM2 expression [10],
and MDM2 ubiquitinates p53 thereby marking the latter for
degradation [11–17]. DNA damage, such as double strand breaks
(DSBs), triggers a cascade of intracellular signaling pathways that
lead to post-translational modifications (e.g., phosphorylation) of
both p53 and MDM2, rendering p53 more stable with enhanced
transcriptional activity [18–20] and MDM2 less stable with
shortened half life [21]. The net result is that DNA damage-
induced protein modifications prolong the time for MDM2 to
cause p53 degradation; this time delay is necessary to generate
p53-MDM2 oscillations [1,3,6,9].
The p53-MDM2 loop is, of course, not isolated from other
molecular interactions in a cell. For example, as depicted in
Figure 1A, the p53-MDM2 loop is embedded in a larger network
that includes AKT, a gene associated with cell survival signaling
pathways. (There are several isoforms of AKT, but among these,
we will specifically refer to AKT1 as AKT in this paper). The
significance of this p53-AKT network (Figure 1A) is highlighted by
the following facts: it involves two known tumor suppressor genes
(p53 and PTEN) [22–26], and two oncogenes (MDM2 and AKT)
[27–29]. Note that the p53-AKT network is composed of two
feedback loops: the mutual antagonism between p53 and AKT
which is a positive feedback loop (edges 1 to 5), and the p53-
MDM2 negative loop (edges 5 and 6). The mutual antagonism
between p53 and AKT is significant because p53 and AKT have
opposite effects on apoptosis. p53 induces the expression of pro-
apoptotic genes such as PUMA, BAX, NOXA, FAS and BAD
[30–34], while AKT inhibits (by phosphorylating) pro-apoptotic
proteins such as BAD [35,36], CASPASE-9 [37] and FKHRL1
[38]. Note that BAD is a common target of p53 and AKT [39],
which may further explain BAD’s crucial role in apoptosis [40].
These considerations led us to hypothesize that the p53-AKT
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4407network is an important module that controls pathways to cell
survival or death [41,42].
The major issue addressed in this paper is the impact of the
oscillatory dynamics of the p53-MDM2 loop on the antagonism
between pro-apoptotic pathways (promoted by high p53 levels)
and pro-survival pathways (promoted by high AKT actvity). We
have shown earlier [41] that the p53-AKT network predicts an all-
or-none (bistable) switching behavior between pro-survival and
pro-apoptotic states, and will now show how this switch is affected
by p53-MDM2 oscillations.
Results
Model Formulation
The model mechanism considered here is shown in Figure 1B; it
will be referred to from hereon as the Model. It is an extension of a
model we previously studied (model Q3 in Ref. [41]) which
exhibits a bistable switch between pro-survival and pro-apoptotic
cellular states. The said model extension involves two additional
variables, namely, the mRNA transcripts of the MDM2 and PTEN
genes; these transcripts are symbolized by mdm2 and pten,
respectively, in Figure 1B. The inclusion of mdm2 introduces a
time delay in the negative feedback loop between p53 and MDM2
proteins, and increases the potential for oscillations. The dynamics
of the Model is described by the set of ordinary differential
equations (ODEs) and parameter values that are listed in Table 1.
Post-translational modifications of p53 and MDM2 due to DNA
damage are assumed to be reflected in an increase of the rate
parameter k0 (for p53 synthesis and activation) and of the rate
parameter dMDM2a (for degradation of active MDM2). Another
assumption made is that k0 and dMDM2a are directly proportional to
IR intensity (r), that is, k0=k 0,basal+k0,IR*r and dMDM2a=
dMDM2a,basal+dMDM2a,IR*r. The justification of this assumption is
based on the many known pathways associated with IR-induced
DNA damage that upregulate p53 and down-regulate MDM2 (see
Figure S1 of Supplemental Data for details).
Figure 1. (A) Qualitative network showing mutual antagonism between AKT and p53. An arrow means a pathway that leads to activation or
upregulation; a hammerhead represents inhibition or downregulation. AKT is antagonized by p53 via edges 1–3, and p53 is antagonized by AKT via
edges 4–5. A p53-MDM2 negative feedback loop is shown by edges 5 and 6. (B) The oscillatory p53-AKT model (the Model). The rate expressions vi’s
are given in Table 1. Note: mdm2 and pten denote mRNAs of MDM2 and PTEN gene, respectively. Mechanisms of the p53-AKT mutual antagonism:
the network is activated by two cellular events namely growth factor stimulation and cellular stress. The former leads to phosphorylation of PIP2
(phosphatidyl inositol-4,5-bisphosphate) to PIP3 (Phosphatidyl inositol 3,4,5. triphosphate) and thereby PIP3-mediated activation of AKT [43]. Active
AKT (AKTa) phosphorylates MDM2 leading to MDM2a translocation to the nucleus [44] where it inhibits p53, and thereby promotes cell survival [45–
50]. Under cellular stress however, transcriptionally active p53 induces PTEN [51–54] among other target genes [55]. PTEN antagonizes AKT-mediated
cell survival by deactivating PIP3 through efficient dephosphorylation [56]. p53-dependent transcription of PTEN upon irradiation-induced DNA
damage has been reported in MCF-7 (human breast cancer epithelial), A172 (human glioblastoma), MEF (mouse embryonic fibroblasts) and tissues of
mouse small intestine, colon, kidney and liver [57–59] where p53 oscillations are also observed [1,3–5,60].
doi:10.1371/journal.pone.0004407.g001
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The steady states of the Model are determined by equating all the
right-hand sides of the ODEs in Table 1 to zero, and solving for
the roots of the resulting system of algebraic equations (see
Materials and Methods). The steady states of p53 and active MDM2
(MDM2a) as functions of r are shown in Figure 2. The Model
exhibits multiplicity of steady states within a range of r (6 to 20.8
Gy – in Figure 2). Within this range of r, the high-p53
(correspondingly, low-MDM2a) steady states are all locally stable
nodes, and the middle branch of steady states are all unstable
saddle points. Decreasing from the right-knee of the steady state
curves to r ,16 Gy, the dynamics about the low-p53 (high-
Mdm2a) branch of steady states is damped oscillatory (stable
spiral). The steady states enveloped by the gray dotted curves in
Figure 2 exhibit unstable spirals that lead to sustained oscillations
(limit cycles). The peaks and troughs of these periodic oscillations
are indicated by the dots above and below the steady states,
respectively. It is interesting to note that the steady state at r=0
Gy is a stable spiral (damped oscillations); this is reminiscent of
reported experimental observations of damped oscillations in some
cell populations that are not exposed to DNA damage-causing
radiation [3].
Table 1. Kinetic rate equations and parameters of the Model.
Differential Equations Kinetic Parameters
Chosen values Range
d[p53]/dt = v0 -v 1 -v 2 k0,basal=0.02 0.005–0.2
d[AKTa]/dt = v8 -v m8 kd=0.02 0.02–0.2
d[MDM2a]/dt = v6 -v Q6 -v 9 k2=0.0625 0.0184–0.092
d[MDM2]/dt = v10 -v 3 -v 6+vQ6 j2=0.01 0.03–0.3
d[mdm2]/dt = v4+v5 -v 7 k5=0.0375 0.024
d[PTEN]/dt = v14 -v 15 j5=0.5 ,1
d[pten]/dt = v11+v12 -v 13 k6=22 22(Ref. [81])
d[PIP3]/dt = v16 -v m16 j6=0.6 0.560.1 (Ref. [81])
kQ6=0.5 0.0000297–2.92
[AKT_Tot] = [AKT]+[AKTa] jQ6=0.1 0.00238–2.23
[PIP_Tot] = [PIP2]+[PIP3] k8=20 ,20
j8=0.1 ,0.1
v0 =k 0 km8=0.2 0.0000297–2.92
v1 =k d * [p53] jm8=0.1 ,0.1
v2 =k 2 * [MDM2a] * [p53]/(j2+[p53]) k10=0.02 (New) (Ref. [6])
v3 =d MDM2 * [MDM2] pmdm2=0.0009 (New) (Ref. [6])
v4 =p mdm2 dmdm2=0.01 (Ref. [6])
v5 =k 5 * [p53]
n2/(j5
n2+[p53]
n2)d MDM2=0.005 0.0028–0.0347
v6 =k 6 * [AKTa] * [MDM2]/(j6+[MDM2]) dMDM2a,basal=0.005 0.0028–0.0347
vQ6 =k Q6 * [MDM2a]/(jQ6+[MDM2a]) k11=0.006 ,0.006
v7 =d mdm2 * [mdm2] j11=2 .1
v8 =k 8 * [PIP3] * [AKT]/(j8+[AKT]) dPTEN=0.0054 0.0025–0.0083
vm8 =k m8 * [AKTa]/(jm8+[AKTa]) ppten=0.0009 (New) –
v9 =d MDM2a * [MDM2a] dpten=0.01 (New) –
v10 =k 10 * [mdm2] k14=0.02 –
v11 =k 11 * [p53]
n1/(j11
n1+[p53]
n1)k 16=0.15 ,0.15
v12 =p pten j16=0.1 ,0.1
v13 =d pten * [pten] km16=73 7364.4
v14 =k 14 * [pten] jm16=0.5 0.1–1
v15 =d PTEN * [PTEN] n1,n 2=4
v16 =k 16 * [PIP2]/(j16+[PIP2]) k0, IR=0.0025 (New)
vm16 =k m16 * [PTEN] * [PIP3]/(jm16+[PIP3]) dMDM2a,IR=0.0025 (New)
[AKT_Tot]=1
Note: [PIP_Tot]=1
k0 =k 0,basal+k0,IR *r * exp(-l*t)
dMDM2a =d MDM2a,basal+dMDM2a,IR *r * exp(-l*t)
New kinetic rate equations and parameters (relative to those used in Ref. [41]) are indicated. Time is in minutes; concentration is in mM.
doi:10.1371/journal.pone.0004407.t001
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p53, mdm2, MDM2 and MDM2a increase with increasing r
(Figure S2 of Supplemental Data), in accord with experimental
observations [3]. Furthermore, the oscillation frequencies of p53,
mdm2, MDM2 and MDM2a are identical. The Model predicts
oscillation periods of 3.5 to 5.2 hours, well within the reported
range of experimental values [3].
The Model also reproduces experimental measurements of the
time separation or delay (1.2–1.9 hrs) between the peaks of
MDM2a and p53 oscillations. Generally, these time delays are not
sensitive to r (Figure S2 of the Supplemental Data). The Model also
predicts that the amplitudes of the oscillations of active AKT,
PIP3, pten mRNA and PTEN will be difficult to measure
experimentally because the concentration differences between
crests and troughs are less than 4% of the mean concentration
(data not shown) – this could explain why oscillations in these
molecules have not been reported so far.
Cells exposed to increasing IR intensities
Computer experiments using the Model were performed to
simulate the behavior of a cell that is exposed to a pulse of IR with
fixed intensity r. For each computer simulation, the initial cellular
levels of the proteins and transcripts are those of the steady states
of a cell that is not exposed to IR (that is, the steady state of the
Model with r=0 Gy). As we increase r in the range where limit
cycle oscillations are exhibited, the system initially displays a high-
amplitude oscillation that settles down to the unique limit cycle
with smaller amplitude at each r. Initially large amplitude p53
oscillations are observed in experiments with single cells [3]. The
peaks of these initial oscillations are shown as black squares in
Figure 3, and superimposed with the steady-state curve of mdm2.
This figure shows that the initial peaks increase with r and that
there is a particular r (symbolized by r*) where the system crosses
a boundary surface associated with the unstable steady states (the
dotted middle branch of steady states) and gets attracted to the
upper branch of stable steady states. Since r* is less than the value
of r corresponding to the right-knee of the steady state curve, we
refer to r* as an early-switching point.
Effect of cell-cell variation
In our computer simulations, cell-to-cell variability is reflected
in the distribution of initial concentrations of all the molecular
Figure 2. Steady states of (A) p53 and (B) active MDM2 (MDM2a) as a function of the intensity of ionizing radiation, r. Local stability
of these states is indicated as either stable (black curve: stable nodes; dark gray curve: stable spirals) or unstable (broken black curve: saddle points;
light gray curve: limit cycles). Limit cycle oscillations whose amplitudes are shown by the dots arise from the unstable steady states (light gray curve)
in the lower (A) or upper (B) branch of the steady state curves.
doi:10.1371/journal.pone.0004407.g002
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concentration is varied around its steady state concentration at
r=0 Gy, with deviations ranging from 0 up to 200% of the steady
state (this range is divided equally into 100 intervals and then
randomly permutated to generate 101 Latin sets of initial
conditions in each Latin hypercube sample). A total of 10
independent Latin hypercube samplings are carried out. For each
Latin set of initial concentrations, trajectories are computed for
each r within the range where there are multiple steady states (6 to
20.8 Gy). The percentages of sets of initial concentrations that lead
to high-p53 steady states are given in Figure 4. Note that 10–20%
of initial conditions can lead to an early-switching point at r equal
to 8 Gy. At 18 Gy about 90% of the cells are predicted by the
Model to make this transition. Thus, switching from the oscillatory
state to the high-p53 state can be induced by cell-cell variations in
their initial concentrations at r that are significantly lower than
that corresponding to the right-knee of the steady-state curve (see
Figure 2). Nevertheless, the propensity for early switching to high-
p53 states becomes more deterministic (less dependent on cell-cell
variations) as r increases.
Effect of cell-type variation
Measured basal concentrations of p53 in seven different cell
lines range from about 1610
4 to 22610
4 molecules per cell [6],
suggesting a cell type-dependent rate of p53 synthesis, and
therefore a significant variation in the value of the parameter
k0,basal of the Model. In addition, several reports [61–63] have
documented cell-type specific post-translational modifications of
various DNA-binding domains of p53 – suggesting that the model
parameter j5 (associated with p53’s affinity to the promoters of
target genes) is also subject to wide variations depending on cell
types. We investigated how these cell-type specific differences
affect the behavior of the system by varying the parameters k0,basal
and j5. For each combination of k0,basal and j5, a steady-state curve
is computed. We sampled 4896 combinations of k0,basal and j5 , and
determined their corresponding steady-state curves. All steady-
state curves with multiple steady states exhibit either limit cycles or
damped oscillations, or both, at the low-p53 steady state branch.
Altogether, three general types of bifurcation curves or switching
behavior are obtained among the 4896 parameter combinations
(Figure S3 of the Supplemental Data):
1. Monostable (observed in 9% of the steady state curves). The
only state of the system is a high-p53 stable node and no
oscillation is manifested. This occurs at relatively high p53
production rate and fast dissociation rate of p53 from promoter
site.
2. Early switch (observed in 87% of the steady state curves). This
is the predominant type observed.
3. Saddle-node switch (observed in 4% of the steady state curves).
For this type, the system switches to high-p53 state exactly at
the right-knee of the curve.
Thus, the early switching phenomenon is likely to arise in cell
types that exhibit p53 oscillations.
Consequences of p53 oscillations on expression of target
genes
Since p53 is a transcription factor with many target genes [64],
it is of interest to determine what the effects of p53 oscillations are
Figure 3. The steady-state curve of mdm2 mRNA is plotted as a function of the intensity of ionizing radiation, r. The black squares
indicate the first peaks of the mdm2 oscillations when the Model is simulated at different values of r, with each simulation having identical initial
conditions (equal to the steady states of the system at r = 0 Gy). The vertical line at r=r*=13.8 Gy marks the value where the peak of mdm2
oscillation is attracted to the upper branch of steady states.
doi:10.1371/journal.pone.0004407.g003
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considered a simplistic model for the expression of a representative
p53-target gene X. This model includes the rate equations v11,v 13,
v14 and v15 shown in Figure 1B. The time-course of an oscillatory
p53 is estimated by p53 ½  oscillatory t ðÞ~ M z Asin
2p
P
t

, where
M is the mean p53 level between the crest and trough, A is the
oscillation amplitude, and P is the oscillation period. The values of
the parameters M, A, and P depend on r, and these values are
estimatedfromtheoscillationsgeneratedinFigure2.Theotherrate
expressionsandallthekineticparametersofthissimplisticmodelare
identical to those used in the Model (Figure 1B).
Figure 5A shows examples of temporal profiles of Xp (protein of
p53-target gene X) expression for both non-oscillatory and
oscillatory p53. As clearly shown, the rate of Xp synthesis is
significantly increased when p53 oscillates. Figure 5B shows that
the steady state of Xp is increased due to p53 oscillations for the
entire range of r where limit cycles are manifested, despite the fact
that the mean level of p53 oscillations is equal to that of non-
oscillatory p53. We observe that the steady state level of Xp
depends, not on the period P of p53 oscillations (data not shown),
but on the mean (M) and amplitude (A) of the oscillations. The
steady state levels of Xp increase with A, as depicted in Figure 5C.
Many examples of the target protein Xp can be cited from the
literature. For example, the cyclin-dependent kinase inhibitor p21
is a transcriptional target of p53 and has been observed to oscillate
in response to p53-MDM2 oscillations upon irradiation in a wild-
type human cell population [2]. In addition, cDNA microarray
data analysis of p53 target genes revealed 51 genes whose mRNA
levels oscillate [65].
To investigate whether p53 oscillations could also induce higher
levels of expression of target genes with slow expression kinetics,
simulations similar to Figure 5B are performed for each of the
following four cases: (i) p53 binding affinity to gene promoter is
decreased 2.5 fold, (ii) p53 induction of genes occurs 8 hrs post-
irradiation, (iii) p53 transcriptional rate is decreased 6 fold, and (iv)
target protein degradation rate is decreased 4 fold. Case (i) assumes
that p53 binding to a promoter affects the timing of gene
transcription. Lower p53 binding affinity to promoters has been
invoked by others [66,67] to explain the rapid induction of cell
cycle genes (within 2 hrs) compared to the intermediate-to-late
induction of apoptotic genes (4 to 8 hrs) post-irradiation. Case (ii)
considers the alternative mechanism whereby late-responsive
genes require p53 to recruit specific transcriptional co-factors for
their induction, as reviewed recently [67]; the time required to
recruit and upregulate the specific co-factors all contribute to the
delayed expressions of late p53-responsive genes. Case (iii)
accounts for the scenario where a slow rate of transcription leads
to corresponding slow protein expression kinetics, and case (iv)
considers proteins that take a comparatively longer time to attain
steady state upon induction of expression because of their slow
degradation rates. Simulation results show that oscillatory p53
induces higher level of gene expressions in all four possible causes
of slow dynamics of gene expression (Figure S4 of the Supplemental
Data).
p53-transcriptional regulation of apoptosis
Here, we present a model that includes explicitly the
downstream signaling pathways from p53 and AKT to apoptosis,
Figure 4. Percentage of Latin sets of initial concentrations leading to high-p53 states. The initial concentrations of all molecular species
are varied simultaneously, with deviations ranging from 0 up to 200% of the steady state concentration at r = 0 Gy (range is divided equally into 100
intervals). Hypercube sampling, which involves random permutations of these intervals, is used to select 101 unique Latin sets of initial conditions.
The percentage of these sets of initial conditions leading to high-p53 state at various selected r is computed. A total of 10 independent hypercube
samplings are performed and the result of each hypercube sample is shown in the figure as a bar.
doi:10.1371/journal.pone.0004407.g004
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caspase-dependent apoptosis. We focus on the mitochondrial
pathway because excessive DNA damage induces apoptosis via the
mitochondrial pathway. The role of the BCL2 protein family in
regulating this intrinsic pathway is well established. Some
members of this family are anti-apoptotic while others are referred
to as pro-apoptotic because they bind and inhibit the action of the
anti-apoptotic members. DNA damage increases the rate of p53-
dependent transcription of pro-apoptotic members such as BAX
[31] and BAD [34]. Examples of anti-apoptotic members are
BCL-2 [68] and BCL-XL [40,69]. Excessive downregulation of
BCL-2 and BCL-XL triggers caspase-dependent apoptosis
[69,70]. Furthermore, the ratio of the levels of BAX to BCL-2
can be a determinant of apoptosis, as has been illustrated in both
experimental and modeling studies [71,72]. AKT enters the
picture because it phosphorylates BAD, thereby inhibiting the
binding of BAD with BCL-XL [35,36], and consequently
promoting cell survival. The p53-AKT Model is modified to
include the aforementioned steps as shown in Figure 6 and Table 2
(the resulting network will be referred to as the Apoptotic Model).
The following assumptions are made: (1) p53-dependent tran-
scription of bax and bad is assumed to decay exponentially with
the same timescale l as the rate of DNA damage repair. This is
because phosphorylation of p53, especially at Serine 46 by DNA
damage signal transducers such as ATM and DNA-PK, is needed
to express pro-apoptotic proteins (see Figure S1 of the Supplemental
Data); (2) As p53 first induces the expression of cell-cycle arrest and
DNA damage repair genes, followed by pro-apoptotic genes (see
[66,67,82,83]), a Hill-type function of time after irradiation is
included as a factor in both v17 and v24. This factor incorporates a
time delay for the expressions of bax and bad, following the
expressions of mdm2 and pten; (3) The rate equations and kinetic
parameters values associated with the reactions of bax, BAX and
BCL-2 are set to be identical to those of bad, BAD and BCL-XL,
respectively. Note that Table S1 (in Supplemental Data) further
summarizes and compares the kinetic parameter values used in the
Model (Figure 1) and the Apoptotic Model (Figure 6).
In the computer simulations, the presence of DNA damage is
reflected in the values of the parameters k0 and dMDM2a.
Furthermore, DNA damage is assumed to decay exponentially
with timescale l - this assumption is based on the observation that
DNA damage repair reduces the number of DSBs exponentially
after exposure to IR doses ranging from 0.2 to 80 Gy [73].
Therefore, both k0 and dMDM2a are assumed to decay exponentially
to their respective basal levels according to the following
expressions: k0=k 0,basal+k0,IR*r*exp(-lt) and dMDM2a=d MDM2a,basal+
dMDM2a,IR*r*exp(-lt).
Representative values of l are used in the simulations: l=0,
0.0005, and 0.001 (corresponding, respectively, to no repair, slow,
and moderate repair rates – as inferred from experiments [73]).
For all simulations, the initial state of the Apoptotic Model is set to its
steady state at r=0 Gy. In accordance with experimental
Figure 5. Consequences of p53 oscillations on gene expression. (A) Time courses of Xp expression induced by both non-oscillatory (gray)
and oscillatory p53 (black) shown in the upper panel (this oscillation profile of p53 is similar to the limit cycle of the Model at r =12Gy). The level of
the non-oscillatory p53 is equal to the mean of the oscillating values of p53. (B) Steady state level of Xp induced by both non-oscillating (gray curve)
and oscillating (black curve) p53 for the entire range of r where limit cycle exists in the Model. The black curve is obtained by taking the average of
the crest and trough of Xp at steady state. Similarly, the oscillation profiles of p53 at each r are estimated from the limit cycle of the Model. The level
of non-oscillatory p53 is equal to the mean of the oscillatory p53. (C) Steady state level of Xp induced as a function of p53 oscillation amplitude.
Parameter values used in the simulations (see text): the mean (M) and period (P) of oscillatory p53 are fixed at 0.5 mM and 4 hr, respectively. The trend
shown in (C) is similar to those obtained using other values of p53 oscillation amplitudes (A=0 to 0.5 mM), means (M=0.1 to 2 mM) and periods (P=4
to 7 hrs).
doi:10.1371/journal.pone.0004407.g005
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doi:10.1371/journal.pone.0004407.g006
Table 2. Kinetic rate equations and parameters of the model depicted in Figure 6.
Differential Equations Kinetic Parameters
d[bax]/dt = v17 -v 18 k17,k 24=0.006
d[BAX]/dt = v19 -v 20 -v 23 j17,j 24=2
d[BCL-2]/dt = v21 -v 22 -v 23 km17,k m 24=400
d[bad]/dt = v24 -v 25 k19,k 26=0.04
d[BAD]/dt = v26 -v 27 -v 30 -v 31+vm31 k21,k 28=0.00048
d[BADp]/dt = v31 -v m31 -v 32 k23,k 30=600
d[BCL-XL]/dt = v28 -v 29 -v 30 k31=44
j31=0.01
v17 ={ k 17 * [p53]
n3/(j17
n3+[p53]
n3)} * {t
n3/(km17
n3+t
n3)} *exp(-l*t) km31=0.01
v18 =d bax * [bax] jm31=10
v19 =k 19 * [bax] dbax,d bad=0.001
v20 =d BAX * [BAX] dBAX,d BAD,d BADp=0.00054
v21 =k 21 dBCL-2,d BCL-XL=0.0036
v22 =d BCL-2 * [BCL-2] n3,n 4=4
v23 =k 23 * [BAX] * [BCL-2]
v24 ={ k 24 * [p53]
n4/(j24
n4+[p53]
n4)} * {t
n4/(km24
n4+t
n4)} *exp(-l*t)
v25 =d bad * [bad]
v26 =k 26 * [bad]
v27 =d BAD * [BAD]
v28 =k 28
v29 =d BCL-XL * [BCL-XL]
v30 =k 30 * [BAD] * [BCL-XL]
v31 =k 31 * [AKTa] * [BAD]/(j31+[BAD])
vm31 =k m31 * [BADp]/(jm31+[BADp])
v32 =d BADp * [BADp]
The values of the kinetic parameters associated with the reactions of bax, BAX and BCL-2 are assumed to be identical to those of bad, BAD and BCL-XL, respectively.
Time is in minutes; concentration is in mM.
doi:10.1371/journal.pone.0004407.t002
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and BCL-XL are used as markers for the progress of apoptosis.
For the purpose of exploring the qualitative behavior of the
Apoptotic Model, and since there are no reported quantitative
measurements, we arbitrarily assumed that a cell commits to
apoptosis upon the decrease of either BCL-2 or BCL-XL to less
than the chosen apoptotic threshold of 1% of its steady state level
at r=0 Gy. The number of p53 pulses needed to deplete BCL-2
below the apoptotic threshold level is determined. As shown in
Figure 7, fewer p53 pulses are required as r is increased, and in
range of r ,8G yt o,13 Gy the number of p53 pulses needed are
more or less constant. The sharp decrease in the number of p53
pulses for r .14 Gy is due to the switch to the upper branch of
p53 steady states. Interestingly, for fixed r, more p53 pulses are
needed as the repair rate is increased.
As shown in Figure 7, a wide range of r generates 3 to 4 pulses
of p53. To investigate whether this small number of pulses is
sufficient to induce higher levels of target gene expression, protein
levels of a p53 target gene (Xp) induced by oscillatory and non-
oscillatory p53 are compared at 1200 min (this time period
corresponds to 3 to 4 p53 pulses). Indeed, our simulations show
that 3 to 4 pulses of p53 are sufficient to induce higher levels of
expression of both early and late responsive target genes for the
entire range of r where limit cycles are manifested (see Figure S5
of the Supplemental Data). These results hold for all time points.
Discussion
Our earlier modeling work [41] demonstrated that the p53-
AKT network (Figure 1A) has the potential to exhibit switching
behavior between pro-survival (high AKT, low p53) and pro-death
(high p53, low AKT) states. Originating from the mutual
antagonism between p53 and AKT, the switching dynamics is
associated with transitions between two stable steady states
(bistability) that coexist under the same parameters [41]. Within
the p53-AKT network is a negative feedback loop between p53
and MDM2 (steps 5 and 6 in Figure 1A). Kinetic models focusing
on this p53-MDM2 loop have been proposed [1,3,6–9] to explain
the experimentally observed oscillations of p53 and MDM2 [1–6];
however, the physiological importance of these oscillations
remains unclear. The present work is based on the hypothesis
that the physiological significance of these p53 oscillations could be
found in their role in regulating the switching behavior of the p53-
AKT network between pro-survival and pro-death states.
We have shown in this paper that the p53-AKT network (the
Model shown in Figure 1B), in addition to its potential for bistable
behavior, is capable of generating sustained oscillations in p53 and
MDM2, and that these oscillations are predicted to occur only
within a range of IR intensities (r) and only in the low-p53 (pro-
survival) branch of steady states (Figure 2). Using model
parameters that are biologically plausible, the Model predicts
oscillation periods of 3.5 to 5.2 hrs – well within the reported
range of experimental values [3]. We also found that the
oscillation frequencies generally increase with increasing r (Figure
S2 of Supplemental Data), in accord with experimental observations
[3]. In addition, the Model reproduces the experimentally
measured time separation (or delay) between peaks of p53 and
MDM2 oscillations (1.2–1.9 hrs), and, furthermore, predicts that
these time delays are insensitive to r (Figure S2 of the Supplemental
Data).
Zhang, Brazhnik and Tyson (2007) [8] have suggested models in
which the p53-MDM2 negative feedback loop is coupled with a
positive loop; in particular, one of these models exhibits multiple
steady states as well as large-amplitude sustained oscillations
around the high-p53 steady states outside the multiple steady-state
regime. These oscillations emerge out of a homoclinic bifurcation
[8]. In contrast, our p53-AKT model exhibits sustained oscillations
Figure 7. Number of p53 pulses (rounded up to the nearest half pulse, vertical axis) required to deplete BCL-2 below the defined
apoptotic threshold level (see text) as function of IR intensity, r, at various DNA damage repair rates l. Note that the number of p53
pulses becomes zero after the early-switching point.
doi:10.1371/journal.pone.0004407.g007
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multiple-steady state ranges of parameters (Figure 2); furthermore,
these oscillations arise out of supercritical Hopf bifurcation. Two
key experimental observations [3] support the Hopf bifurcation
scenario: first, observed p53 oscillations show more variability in
amplitudes than in periods, and, second, the initial p53 pulse is
larger than subsequent pulses, indicating that the initial response
to DNA damage is not sluggish (which would be the case if it were
a homoclinic bifurcation [74]). Simulations using our model do
show that the initial response to DNA damage agrees with the
second experimental observation (see also Figure S6 of the
Supplemental Data); the Model generates p53 pulses with larger
amplitudes, longer periods and larger time delays between peaks of
MDM2 and p53 compared to those generated by a stand-alone
p53-MDM2 oscillator (Figure S7 of the Supplemental Data). In
addition, the Model coupled with downstream pathways to
apoptosis predict that there is a range of IR intensities where the
number of p53 pulses acts as the digital count for the induction of
apoptosis (Figure 7).
A subtle prediction of the Model comes from the computer-
simulated experiments of exposing cells to increasing radiation
intensity – subtle because it is not readily evident from the steady
state bifurcation diagrams (Figures 2 and 3). In these simulations,
the initial condition of the system before IR exposure is always
identical to that of the case where r=0 (let this initial condition be
symbolized by x0 which is a vector in 8-dimensional concentration
space). For values of the parameter r in between those
corresponding to the knees of the steady-state curve in Figure 3,
the unstable middle steady state acts as a boundary between the
top steady state and oscillatory state. Because the system is multi-
dimensional, the boundary that separates the basins of attractions
of the top steady state and oscillatory state (for r,16, see Figure 3)
is a multidimensional surface – let us call this surface S . The
position of S depends on r, and as r is increased, the position of
x0 relative to S moves from one that is located in the basin of
attraction of the oscillatory state to one on the other side of S that
is within the basin of attraction of the top steady state; this switch
occurs at r*, the early-switching point (so-called because r* is less
than the r corresponding to the right knee of the steady state
curve). A cartoon that illustrates the aforementioned ideas is
shown in Figure 8. A scattering of initial conditions around x0
leads to various probabilities of switching from the oscillatory state
to the top steady state; for example, as shown in Figure 4, about
half of all sampled initial conditions around x0 are attracted to the
top steady state at r=r*=13.8 Gy (Figure 4) which is significantly
lower than the value of 20.8 Gy corresponding to the right-knee of
the steady-state curve (Figure 2). These simulations suggest that
because of the instability of the lower steady states where
oscillations exist (Figures 2A and 3), the fluctuations in p53 and
MDM2 increase the probability of crossing S – causing the
abovementioned early switch which can be interpreted as a decrease
in tolerance to death-inducing IR.
Another important result presented in this paper is the
consequence of p53 oscillations on the level of expression of
p53-target genes. It is predicted that at a fixed r where oscillations
exist, p53-target genes are expressed at higher levels compared to
the case where there are no oscillations (Figure 5B). Furthermore,
this increase in expression of target genes is more pronounced as
the amplitude of p53 oscillations becomes larger (Figure 5C). In
the context of the p53-AKT network (Figure 1A), the model
predicts an increase in PTEN expression (thereby promoting the
antagonism against the survival factor AKT) and an increase in
BAX and BAD expression (thereby promoting apoptosis). Thus,
IR exposure that induces p53 oscillations is predicted to sensitize
cells towards apoptotic death. The issue of how p53 oscillations
may influence the determination of cell fate (i.e., between cell cycle
arrest/DNA damage repair versus apoptosis) is not considered in
the present work.
Reported differential sensitivity of mice organs to IR-induced
apoptosis [75] suggests that IR sensitivity is closely linked with p53
oscillations and the proliferation status of cells. The early-switch
phenomenon and the increased expression of p53-target genes due
to p53 oscillations, as discussed in the preceding paragraph, may
be offered as an explanation for this IR-sensitivity. In terms of the
proliferation status of cells, highly IR-sensitive organs such as
spleen and small intestine – in which p53 oscillations have been
observed [4] – are generally composed of proliferating cells,
whereas non-proliferating cells in organs such as the brain are
Figure 8. A cartoon of the p53-MDM2a phase portrait for the cases r,r* and r.r*, where r* is the early-switching point. (A) For
r,r*, the initial state corresponding to r=0 Gy (indicated by x0) is located within the basin of attraction of the limit cycle. (B) At r.r*, x0 is now
located in the basin of attraction of the high-p53 stable node (N). Note: the actual phase portrait is high-dimensional; the two-dimensional portraits
above are given merely to illustrate the basic idea of the origin of the early-switching point.
doi:10.1371/journal.pone.0004407.g008
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oscillations have so far been carried out using proliferating cells
such as breast cancer epithelial [1,3,5,6] and fibroblast cells [2].
The fact that our Model predicts that the oscillations occur around
the low-p53 steady states is consistent with these observed
association between proliferating cells and p53 oscillations.
We would like to offer ways to test the predictions of our model
in the laboratory. Several single cell time-lapse microscopy
experiments (e.g., Ref. [3]) could be performed to validate key
hypotheses generated from the models by taking advantage of the
evidence that not every cell (of the same type) would manifest p53-
MDM2 oscillations when irradiated with the same IR intensity.
For instance, only 40% of MCF-7 cells showed oscillations upon
10 Gy of gamma radiation [3]. Strictly speaking, a cell could only
be in one of the three states: low-p53 (non-oscillatory cells), high-
p53 and oscillatory p53 (oscillatory cells). The key prediction that
p53 oscillations induce higher level of target gene expression could
be tested by semi-quantifying the expression level of a (transfected)
luciferase reporter gene that possesses a p53 promoter sequence
upon irradiation. Oscillatory cells are predicted to express higher
intensity of fluorescence than non-oscillatory cells (of the same
type); comparisons should be made among cells that expressed
similar mean level of p53. Also, an interesting experiment would
be to test whether higher p53-dependent expression of cell cycle
and DNA repair genes in oscillatory cells could lead to faster cell
cycle arrest and repair damage DNA than non-oscillatory cells
upon irradiation. In contrast, the other key prediction that p53
oscillations lower the IR intensity level at which the system
switches to high-p53 state is relatively trickier to perform
experimentally. It involves the determination of cumulative IR
dose that lead to a high-p53 state in each oscillatory and non-
oscillatory cells by increasing the IR dose gradually. Oscillatory
cells are predicted to switch to high-p53 state over a wider range of
cumulative IR dose with lower median than non-oscillatory cells.
Lastly, for the future development of our model, we would like
to point out that besides PTEN, the insulin growth factor-binding
protein 3 (IGFBP3) connects p53 to AKT. Upon DNA damage,
IGFBP3 is upregulated by both p53-dependent and independent
transcription [76,77]. IGFBP3 binds and sequesters IGFs (insulin
growth factors) away from IGFRs (insulin growth factor receptors),
and thereby inhibits AKT activation; active IGF-bound IGFRs
induce the downstream activation of the PI3K/AKT survival
pathway [78]. Surprisingly, through unknown mechanisms,
IGFBP3 could also sensitize cells to the phosphorylation of AKT
by IGFs, which leads to AKT activation [79,80]. Thus, further
experimental studies are needed to resolve the conflicting
relationship between p53, IGFBP3 and AKT.
Materials and Methods
To determine the steady states of the Model, the left-hand sides
of the ODEs in Table 1 are all set to zero and the corresponding
systems of nonlinear algebraic equations were solved numerically
using Maple (version 7.0). The steady states as functions of certain
parameters are referred to as steady-state bifurcation diagrams.
The local stability of the steady states is determined using standard
linear stability analysis, involving the determination of the
eigenvalues of associated Jacobian matrices. To obtain the time-
series trajectories of the species concentrations in the model, the
ODEs are integrated using a modified Rosenbrock formula of
order 2 that is implemented in the MATLAB (The MathWorks,
Natick, MA) platform (version 6.5, Release 13).
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